Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

1.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ.

Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16.

PMID:
22180306
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.

Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, Zhang J, Highsmith WE, Halling KC, Kipp BR.

Hum Pathol. 2013 Jul;44(7):1216-22. doi: 10.1016/j.humpath.2012.11.006. Epub 2013 Feb 4.

PMID:
23391413
[PubMed - indexed for MEDLINE]
3.

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.

Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY.

Oncogene. 2013 Jun 20;32(25):3091-100. doi: 10.1038/onc.2012.315. Epub 2012 Jul 23.

PMID:
22824796
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cancer-associated isocitrate dehydrogenase mutations.

Yen KE, Schenkein DP.

Oncologist. 2012;17(1):5-8. doi: 10.1634/theoncologist.2011-0429. Epub 2012 Jan 10. No abstract available.

PMID:
22234630
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2014 Sep 4;513(7516):110-4. doi: 10.1038/nature13441. Epub 2014 Jul 2.

PMID:
25043045
[PubMed - indexed for MEDLINE]
6.

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.

Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ, Halling KC.

Hum Pathol. 2012 Oct;43(10):1552-8. doi: 10.1016/j.humpath.2011.12.007. Epub 2012 Apr 12.

PMID:
22503487
[PubMed - indexed for MEDLINE]
7.

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU.

J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.

PMID:
22397365
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF.

BMC Cancer. 2011 Feb 8;11:60. doi: 10.1186/1471-2407-11-60.

PMID:
21303542
[PubMed - indexed for MEDLINE]
Free PMC Article
9.
10.

[Gallbladder and bile duct carcinoma. Biology and pathology].

Tannapfel A, Wittekind C.

Internist (Berl). 2004 Jan;45(1):33-41. Review. German.

PMID:
14735242
[PubMed - indexed for MEDLINE]
11.

TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels.

Surrey LF, Frank R, Zhang PJ, Furth EE.

Am J Surg Pathol. 2014 Feb;38(2):224-7. doi: 10.1097/PAS.0000000000000138.

PMID:
24418856
[PubMed - indexed for MEDLINE]
12.

IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.

Borger DR, Zhu AX.

Expert Rev Anticancer Ther. 2012 May;12(5):543-6. doi: 10.1586/era.12.32. No abstract available.

PMID:
22594888
[PubMed - indexed for MEDLINE]
13.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

PMID:
20368543
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Analysis of K-ras gene mutations in periampullary cancers, gallbladder cancers and cholangiocarcinomas from paraffin-embedded tissue sections.

Lee JC, Lin PW, Lin YJ, Lai J, Yang HB, Lai MD.

J Formos Med Assoc. 1995 Dec;94(12):719-23.

PMID:
8541732
[PubMed - indexed for MEDLINE]
15.

Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.

Chuang SC, Lee KT, Tsai KB, Sheen PC, Nagai E, Mizumoto K, Tanaka M.

World J Surg. 2004 Oct;28(10):995-1000. Epub 2004 Sep 29.

PMID:
15573254
[PubMed - indexed for MEDLINE]
16.

Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.

Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT.

Nat Genet. 2013 Dec;45(12):1474-8. doi: 10.1038/ng.2806. Epub 2013 Nov 3.

PMID:
24185513
[PubMed - indexed for MEDLINE]
17.

Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.

Riener MO, Vogetseder A, Pestalozzi BC, Clavien PA, Probst-Hensch N, Kristiansen G, Jochum W.

Hum Pathol. 2010 Nov;41(11):1558-65. doi: 10.1016/j.humpath.2009.12.016.

PMID:
20621328
[PubMed - indexed for MEDLINE]
18.

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.

Xu RF, Sun JP, Zhang SR, Zhu GS, Li LB, Liao YL, Xie JM, Liao WJ.

Biomed Pharmacother. 2011 Feb;65(1):22-6. doi: 10.1016/j.biopha.2010.06.009. Epub 2010 Nov 3.

PMID:
21051183
[PubMed - indexed for MEDLINE]
19.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
[PubMed - indexed for MEDLINE]
Free Article
20.

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M.

Clin Cancer Res. 2006 Mar 15;12(6):1680-5.

PMID:
16551849
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk